title: Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
abstract: The purpose of this study is to investigate whether the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the complement factor H (CFH) gene have a pharmacogenetics effect on the anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). We performed a meta-analysis using databases including PubMed and EMBASE to find relevant studies. 13 published association studies were selected for this meta-analysis, including 2704 patients. For the CFH Y402H polymorphism, anti-VEGF treatment was much less effective in AMD patients with the CFH CC genotype (CC versus TT: odds ratio (OR) = 55, 95% confidence interval (CI), 0.31 to 0.95, P = 0.03; CC versus CT: OR = 0.60, 95% CI, 0.40 to 0.91, P = 0.02; and CC versus CT + TT: OR = 0.59, 95% CI, 0.38 to 0.90, P = 0.02, respectively). In subgroup analysis, CFH Y402H polymorphism was more likely to be a predictor of response for Caucasians (CC versus CT+TT: OR = 0.63, 95% CI, 0.42 to 0.95, P = 0.03). In conclusion, pharmacogenetics of CFH Y402H polymorphism may play a role in response to anti-VEGF treatment for neovascular AMD, especially for Caucasians.
authors.affiliation: Department of Ophthalmology, Quzhou People's Hospital, Quzhou, Zhejiang, PR, China.
authors.forename: Guohai
authors.initials: G
authors.lastname: Chen
authors.affiliation: The Roskamp Institute, Sarasota, Florida, USA.|Department of Ophthalmology, University of South Florida, Tampa, Florida, USA.
authors.forename: Radouil
authors.initials: R
authors.lastname: Tzekov
authors.affiliation: Xiamen Eye Center of Xiamen University, Xiamen, Fujian, PR, China.
authors.forename: Wensheng
authors.initials: W
authors.lastname: Li
authors.affiliation: Department of Ophthalmology, Quzhou People's Hospital, Quzhou, Zhejiang, PR, China.
authors.forename: Fangzheng
authors.initials: F
authors.lastname: Jiang
authors.affiliation: Department of Ophthalmology, Quzhou People's Hospital, Quzhou, Zhejiang, PR, China.
authors.forename: Sihong
authors.initials: S
authors.lastname: Mao
authors.affiliation: Department of Ophthalmology, Quzhou People's Hospital, Quzhou, Zhejiang, PR, China.
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Tong
mesh_terms: D000483:Alleles; D019943:Amino Acid Substitution; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D003062:Codon; D017242:Complement Factor H / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D016017:Odds Ratio; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D003062:Codon; D042461:Vascular Endothelial Growth Factor A; D017242:Complement Factor H